Newswise — LOUISVILLE, Ky., Sept. 19, 2024 /PRNewswire/ -- Eurofins Genomics US is proud to announce the opening of a new world-class oligonucleotide manufacturing facility. The expansion significantly increases manufacturing capacity and capabilities, allowing Eurofins Genomics US to meet the ever-growing global demand for GMP-grade and research use oligonucleotides.
The new GMP facility is designed to provide a state-of-the-art environment for the production of synthetic DNA and RNA, ensuring the highest standards of quality, safety, and efficiency. The new facility's design provides completely segregated production trains for Research Use Only (RUO) and Good Manufacturing Practice (GMP) products. These segregated production trains flow all the way from synthesis to shipping, ensuring that oligonucleotides intended for molecular diagnostic, therapeutic, clinical, and other regulated industries are manufactured in a controlled environment that adheres to the most rigorous quality standards.
Sumit Gupta, president of Eurofins Genomics US, commented, "this marks a significant milestone in our commitment to excellence and innovation in genomics."
The 75,000 ft2 facility incorporates advanced automation and process controls to enhance production efficiency, purity, and traceability; three factors that are particularly important for NGS sequencing applications, such as NGS adaptors and capture panels. In addition, a substantial investment in new equipment will nearly double capacity. This expansion leads to consistent product quality, shorter lead times, and increased capacity to meet the growing demand for high-quality oligonucleotides for both research and regulated industries.
About Eurofins Scientific
Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 62,000 staff across a network of more than 900 independent companies in over 62 countries generally specialized by end client markets and operating more than 1000 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services.
RSS